Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 3/20 | 0.58 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.56 |
| ▸ | SLC34A1 | Q06495 | 3/20 | 0.52 |
| ▸ | FPR1 | P21462 | 1/20 | 0.48 |
| ▸ | VNN1 | O95497 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | NSD2 | O96028 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4239759 | 0.87 | SLC34A1 (0.51) | ARSLC34A1MEN1KMT2APOLB | |
| SCHEMBL4296224 | 0.83 | POLB (0.45) | SLC34A1MEN1KMT2APOLBPDE4D | |
| SCHEMBL4233402 | 0.80 | SLC34A1 (0.54) | ARSLC34A1FPR1MEN1KMT2A | |
| SCHEMBL2857382 | 0.77 | LMNA (0.53) | SLC34A1MEN1KMT2APOLBPDE4D | |
| SCHEMBL4298606 | 0.75 | AR (0.45) | ARSLC34A1MEN1KMT2APOLB | |
| SCHEMBL7935350 | 0.74 | VNN1 (0.60) | MAPK14VNN1NSD2KDM4ETP53 | |
| SCHEMBL4301527 | 0.73 | AR (0.68) | ARSLC34A1KDM4ETP53 | |
| SCHEMBL4296277 | 0.73 | AR (1.00) | ARSLC34A1MEN1KMT2A | |
| SCHEMBL12265091 | 0.73 | PDE4D (0.58) | SLC34A1KDM4EPDE4D | |
| SCHEMBL13664175 | 0.73 | MAPK14 (0.63) | ARMAPK14VNN1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090270361-A1 | Substituted pyrazole derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-29 | — | — | US | disclosed |
| US-20090270361-A1 | Substituted pyrazole derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-29 | — | — | US | disclosed |
| WO-2009119880-A1 | SUBSTITUTED PYRAZOLE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270361-A1 | Substituted pyrazole derivatives and use thereof | CBR3, CBR1, NOX5 | AR 622/4885MAPK14 2637/4885SLC34A1 1375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.